MMED (NASDAQ:MMED) Earns Outperform Rating from Analysts at William Blair

Key Points

• Analysts at William Blair initiated coverage on MMED with an “outperform” rating, and several other major firms (including Mizuho, Wells Fargo, Morgan Stanley and Bank of America) started coverage with mostly buy/overweight ratings; overall there are nine Buys and one Hold, giving MMED a consensus rating of “Moderate Buy” and a consensus target of $22.33.
• MMED opened at $14.35 and is trading near its 52-week low of $14.10 (vs. a 52-week high of $20.48), indicating potential upside relative to analyst price targets.
• MMED is a scaled global medical-technology company that develops, manufactures and markets an integrated suite of solutions for diabetes management, reportedly commercializing all parts of an integrated diabetes management system.

Stock analysts at William Blair started coverage on shares of MMED (NASDAQ:MMED - Get Free Report) in a report issued on Tuesday. The firm set an "outperform" rating on the stock.

MMED has been the topic of several other research reports. Mizuho started coverage on MMED in a report on Tuesday. They set an "outperform" rating and a $21.00 price target on the stock. Wall Street Zen upgraded shares of MMED to a "hold" rating in a research note on Saturday, March 14th. Wells Fargo & Company started coverage on shares of MMED in a report on Tuesday. They set an "overweight" rating and a $26.00 price target for the company. Morgan Stanley initiated coverage on MMED in a research note on Tuesday. They issued an "overweight" rating and a $19.00 price objective on the stock. Finally, Bank of America began coverage on MMED in a report on Tuesday. They issued a "buy" rating and a $27.00 target price on the stock. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, MMED currently has an average rating of "Moderate Buy" and a consensus target price of $22.33.

MMED Stock Performance

MMED opened at $14.35 on Tuesday. MMED has a 52-week low of $14.10 and a 52-week high of $20.48.

MMED Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.